RGX-202 met its Phase 3 Duchenne goal, and new data detail two resolved serious side effects. What families should know before a possible FDA decision.
RGX-202 Duchenne Gene Therapy Met Its Phase 3 Goal as New Data Detail Two Resolved Serious Side Effects
by | Oct 20, 2026 | Uncategorized | 0 comments
Recent Comments